AzurRx (AZRX) Corporate Media Kit

13 MS1819 Doses # Patients Safety* Primary Efficacy Endpoints* Secondary Efficacy Endpoints* Status Daily Dose PERT + • 700 mg • 1120 mg • 2240 mg 20 Hungary, Spain, Turkey Positive CFA Data on 1 st five patients Clinically Meaningful Data on 1 st five patients Initiated Q4 2019 Topline Data Anticipated Q2 2021 * On 1 st five patients MS1819 Phase 2 Cystic Fibrosis Combination Therapy Dose Escalation Study in Patients with Severe EPI